[{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Ironshore Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ironshore Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ironshore Pharmaceuticals","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ironshore Pharmaceuticals","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Ironshore Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

Brand Name : Jornay PM

Molecule Type : Small molecule

Upfront Cash : $525.0 million

September 04, 2024

Lead Product(s) : Methylphenidate Hydrochloride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved

Sponsor : Collegium Pharmaceutical

Deal Size : $525.0 million

Deal Type : Acquisition

blank

02

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

Brand Name : Jornay PM

Molecule Type : Small molecule

Upfront Cash : $525.0 million

July 29, 2024

Lead Product(s) : Methylphenidate Hydrochloride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Discovery

Sponsor : Collegium Pharmaceutical

Deal Size : $550.0 million

Deal Type : Acquisition

blank

03

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : The data presented in the poster may help guide clinicians to target an appropriate dose range of JORNAY PM extended-release capsules CII, which was approved in August 2018 by the U.S. FDA for the treatment of ADHD in patients 6 years and older.

Brand Name : Jornay PM

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 08, 2020

Lead Product(s) : Methylphenidate Hydrochloride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank